The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tiludronate     [(4-chlorophenyl)sulfanyl- phosphono...

Synonyms: acpmd, CHEMBL1350, AC1Q3OOE, SR-41319, BIDD:GT0814, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C08141


High impact information on C08141


Chemical compound and disease context of C08141


Biological context of C08141


Associations of C08141 with other chemical compounds

  • Results showed that: (1) intravenously, SR 41319 induced a dose-dependent inhibition of PCA more pronounced than the EHDP one; (2) in PLA2 assay, marked inhibition was obtained with SR 41319 whereas EHDP was slightly active [6].


  1. Tiludronate: development as an osteoporosis therapy. Chesnut, C.H. Bone (1995) [Pubmed]
  2. Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Barbier, A., Breliére, J.C., Remandet, B., Roncucci, R. Ann. Rheum. Dis. (1986) [Pubmed]
  3. Effect of (chloro-4-phenyl) thiomethylene bisphosphonic acid (SR 41319) on the autoimmune disease activity in MRL/l mice. Barbier, A., Planchenault, C., Breliere, J.C. Agents Actions (1986) [Pubmed]
  4. Effects of 1-hydroxyethylidene-1,1 bisphosphonate and (chloro-4 phenyl) thiomethylene bisphosphonic acid (SR 41319) on the mononuclear cell factor-mediated release of neutral proteinases by articular chondrocytes and synovial cells. Emonds-Alt, X., Brelière, J.C., Roncucci, R. Biochem. Pharmacol. (1985) [Pubmed]
  5. Multiple dose pharmacokinetics of tiludronate in healthy volunteers. Schwietert, H.R., Peeters, P.A., Dingemanse, J., Thiercelin, J.F., Necciari, J., de Bruin, H., Jonkman, J.H. Eur. J. Clin. Pharmacol. (1996) [Pubmed]
  6. Comparative study of etidronate and SR 41319, a new diphosphonate, on passive cutaneous anaphylaxis and phospholipase A2 activity. Barbier, A., Breliere, J.C., Paul, R., Roncucci, R. Agents Actions (1985) [Pubmed]
  7. An economic evaluation of tiludronic acid treatment in Paget's disease of bone. Lafuma, A., Fagnani, F., Meunier, P.J. PharmacoEconomics. (1997) [Pubmed]
WikiGenes - Universities